Sep 10 |
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
|
Aug 10 |
ProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Jun 23 |
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company
|
Jun 18 |
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
|
May 13 |
Shareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years ago
|
May 11 |
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
|
May 9 |
ProQR GAAP EPS of -€0.09, revenue of €4.45M
|
May 9 |
ProQR Announces First Quarter 2024 Operating and Financial Results
|
May 8 |
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
|
Apr 23 |
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
|